Sai Life Sciences FY25 PAT higher by 105% to Rs. 170 Cr

PAT stood at Rs. 88 crore for Q4 FY25 as compared to Rs. 56 crore in Q4FY24, an increase of 57%

Lonza joins CMAC to enhance service offering for specialty, enhanced drug product and particle technologies

Centre for Continuous Manufacturing and Advanced Crystallisation (CMAC) aims to accelerate the digital transformation of CMC development and manufacturing approaches

Granules India completes acquisition of Senn Chemicals

Strengthening capabilities in Peptide Therapeutics and CDMO services

Sai Life Sciences sets up Peptide Research Center in India

The Peptide Research Center is designed to support innovator pharma and biotech companies with specialized services across peptide synthesis, discovery, and advanced modalities, including complex conjugates

Lonza implements streamlined operating model

Lonza’s new simplified and streamlined operating model is designed to support its One Lonza vision and strategy

Cadila launches Cadilose for constipation and hepatic encephalopathy

Lilly plans to more than double US manufacturing investment since 2020 exceeding $50 billion

Company expects to begin building four more domestic manufacturing sites this year and add 13,000 high-wage manufacturing and construction jobs in America

Granules India acquires Swiss Senn Chemicals to foray into peptide and CDMO business

The acquisition aligns with Granules' vision to enter the rapidly expanding peptide-based anti-diabetic and anti-obesity market

Sigachi Industries to invest US $1 mn in establishing R&D Centre in Hyderabad

The company is committed to revolutionizing API development by advancing synthesis and analytical processes that enhance quality and impact lives

Anthem Biosciences files DRHP for Rs. 3,395 crore IPO

Anthem’s business comprises of CRDMO services and the manufacture and sale of Specialty Ingredients